H.C. Wainwright analyst Edward White maintained a Buy rating on Dynavax (NASDAQ:DVAX) Technologies Corp. on Monday, setting a price target of $23, which is approximately 36.58% above the present share price of $16.84.
White expects Dynavax Technologies Corp. to post earnings per share (EPS) of $0.04 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Dynavax, with an average price target of $20.67.
The analysts price targets range from a high of $23 to a low of $19.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $52.77 million and a net profit of $9.17 million. The company's market cap is $1.93 billion.
According to TipRanks.com, H.C. Wainwright analyst Edward White is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.7% and a 44.73% success rate.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.